US High Growth Tech Stocks Spotlight Featuring 3 Top Picks

Over the last 7 days, the United States market has risen 1.2% and is up 13% over the last 12 months, with earnings forecast to grow by 18% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and robust financial health to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 26 stocks from our US High Growth Tech and AI Stocks screener.

Let’s dive into some prime choices out of from the screener.

Rhythm Pharmaceuticals (RYTM)

Simply Wall St Growth Rating: ★★★★★★

Overview: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops therapies for rare neuroendocrine diseases in the United States and internationally, with a market cap of $6.09 billion.

Operations: Rhythm Pharmaceuticals generates revenue primarily through the development and commercialization of therapies for patients with rare diseases, amounting to $239.92 million.

Rhythm Pharmaceuticals is charting a promising trajectory with its innovative treatments in the realm of rare metabolic disorders. Recently, Health Canada endorsed IMCIVREE for managing weight in patients with acquired hypothalamic obesity, marking a significant milestone as it becomes the first targeted therapy approved for this condition in Canada. This approval was bolstered by robust results from the TRANSCEND trial, which demonstrated an 18.8% reduction in BMI compared to placebo. Looking ahead, Rhythm’s revenue is projected to climb by 38.8% annually, outpacing the broader US market growth of 13.9%. Despite current unprofitability, forecasts suggest a bright financial future with an anticipated profit surge and an impressive return on equity expected to hit 36.6% in three years, underscoring its potential within high-growth biotech sectors.

• Get an in-depth perspective on Rhythm Pharmaceuticals’ performance by reading our health report here.

• Evaluate Rhythm Pharmaceuticals’ historical performance by accessing our past performance report.

Advanced Energy Industries (AEIS)

Simply Wall St Growth Rating: ★★★★★★

Overview: Advanced Energy Industries, Inc. specializes in precision power conversion, measurement, and control solutions globally and has a market cap of approximately $11.70 billion.

Operations: Advanced Energy Industries generates revenue primarily from its Power Electronics Conversion Products, totaling $2.04 billion. The company operates across the United States, Asia, Europe, and other international markets.

Advanced Energy Industries has demonstrated robust growth, with a notable 158.4% increase in earnings over the past year, significantly outpacing the electronic industry’s 19% average. This surge is underpinned by strategic expansions like the launch of the DF150 power supply, tailored for extreme-environment applications—a move that enhances its product lineup and taps into new market segments. Furthermore, with an annual revenue growth forecast at 21.8%, AEIS is set to exceed the US market projection of 13.9%. The firm also maintains a strong commitment to shareholder returns, as evidenced by consistent quarterly dividends and an aggressive share repurchase strategy that saw $364.22 million spent on buybacks since 2015. These financial maneuvers are supported by a projected annual profit growth rate of 43.5%, positioning AEIS well within high-tech sectors requiring dependable energy solutions.

• Unlock comprehensive insights into our analysis of Advanced Energy Industries stock in this health report.

• Learn about Advanced Energy Industries’ historical performance.

Insmed (INSM)

Simply Wall St Growth Rating: ★★★★★★

Overview: Insmed Incorporated focuses on developing and commercializing therapies for serious and rare diseases across the United States, Europe, Japan, and other international markets with a market cap of $22.22 billion.

Operations: The company generates revenue primarily from developing and commercializing therapies for rare diseases, totaling $1.14 billion.

Insmed, navigating through a transformative phase, has recently reaffirmed its robust revenue projections for 2026, anticipating between $1.25 billion and $1.40 billion from its flagship products BRINSUPRI® and ARIKAYCE®. This outlook is bolstered by the FDA’s priority review of ARIKAYCE®, potentially accelerating its market reach. Amidst these developments, CFO Sara Bonstein announced her departure, ensuring a transition that aligns with the upcoming earnings call. These strategic maneuvers underscore Insmed’s proactive approach in fortifying its market position while navigating executive transitions and regulatory landscapes effectively.

• Click here to discover the nuances of Insmed with our detailed analytical health report.

• Understand Insmed’s track record by examining our Past report.

Turning Ideas Into Actions

• Investigate our full lineup of 26 US High Growth Tech and AI Stocks right here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Streamline your investment strategy with Simply Wall St’s app for free and benefit from extensive research on stocks across all corners of the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven’t yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com